Colleges
Biography
Kevin Talbot qualified in medicine (MB BS) with Distinction from the University of London and trained in Neurology in London and Oxford. He joined the laboratory of Professor Kay Davies in 1995 to work on the childhood motor neuron disorder spinal muscular atrophy, which has remained a major focus of his research ever since. From 1998-2001 he was Clinical Lecturer in Neurology and from 2001-2006 held an MRC Clinician Scientist Fellowship. He leads a multidisciplinary team providing a clinical service for patients with motor neuron disease from all over the South of England. In 2010 he became Professor of Motor Neuron Biology
Awards, Training and Qualifications
- MB BS University of London 1990
- DPhil University of Oxford 1998
- FRCP Royal College of Physicians, London 2006
Kevin Talbot
MB BS, DPhil, FRCP
Head of Department and Professor of Motor Neuron Biology
Research groups
Websites
-
Division of Clinical Neurology
Research Centre
-
Kavli Institute for Nanoscience Discovery
Research Centre
Research Summary
The main aim of my research is to identify targets for therapy in motor neuron diseases such as amyotrophic lateral sclerosis (ALS). In particular, we use laboratory models including motor neurons from induced pluripotent stem cells from patients to understand why motor neuron integrity fails in the presence of certain genetic mutations (eg; TDP-43 or C9orf72 in ALS). We also use these models to identify drug targets. Our work takes place in the context of a larger team of researchers in Oxford interested in translational research in neurodegenerative diseases, and we have many national and international collaborations. We are active members of the UK MND Research Institute.
DPHIL PROJECTS
Professor Talbot is not currently accepting new DPhil students.
Sources of Funding
- Motor Neuron Disease Association 2001-2026
- MND Scotland 2023-2026
- My Name'5 Doddie Foundation 2019-2026
- Alan Davidson Foundation 2022-2025
- NIHR 2022-2027
Recent publications
-
Improving the measurement properties of the Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised (ALSFRS-R): deriving a valid measurement total for the calculation of change.
Journal article
Young CA. et al, (2024), Amyotroph Lateral Scler Frontotemporal Degener, 1 - 10
-
Mutant GGGGCC RNA prevents YY1 from binding to Fuzzy promoter which stimulates Wnt/β-catenin pathway in C9ALS/FTD.
Journal article
Chen ZS. et al, (2023), Nat Commun, 14
-
Data-independent acquisition proteomics of cerebrospinal fluid implicates endoplasmic reticulum and inflammatory mechanisms in amyotrophic lateral sclerosis.
Journal article
Dellar ER. et al, (2023), J Neurochem
-
C9orf72-ALS human iPSC microglia are pro-inflammatory and toxic to co-cultured motor neurons via MMP9.
Journal article
Vahsen BF. et al, (2023), Nat Commun, 14
-
PRMT inhibitor promotes SMN2 exon 7 inclusion and synergizes with nusinersen to rescue SMA mice.
Journal article
Kordala AJ. et al, (2023), EMBO Mol Med